Why Really don't we see far more head-to-head trials of competitor medicines? The solution is fairly simple, honestly: hazard management. For medication which are on patent, such as GLP-1s, conducting a demo with no invest in-in from the pharmaceutical firm is simply too high-priced — we will not run a demo Until anyone presents the drug without